Olink data for 'Identification of soluble biomarkers that associate with distinct manifestations of long COVID'

Olink analysis output from plasma samples from healthy donors and donors with post-acute sequelae of SARS-CoV-2 infection. Data sourced from two cohorts - UK and Sweden based. UK patients with long covid start with CA. UK healthy controls start with CO. Swedish donors only include patients with long covid and start with KLIMP. Assays from the following panels were tested: Explore 384 Cardiometabolic, Explore 384 Cardiometabolic II, Explore 384 Inflammation, Explore 384 Inflammation II, Explore 384 Neurology, Explore 384 Neurology II, Explore 384 Oncology, Explore 384 Oncology II. Data relates to the manuscript titled 'Identification of soluble biomarkers that associate with distinct manifestations of long COVID'.本数据集为Olink检测分析的产出结果，样本来源于健康供者以及感染新冠病毒后出现急性后遗症（long COVID，俗称长新冠）供者的血浆标本。数据来源于英国与瑞典两个地域队列：英国队列中，长新冠患者样本以"CA"作为标识前缀，健康对照样本以"CO"作为标识前缀；瑞典队列仅纳入长新冠患者，其样本以"KLIMP"作为标识前缀。本次检测使用了以下检测面板：Explore 384 心血管代谢组、Explore 384 心血管代谢组II、Explore 384 炎症组、Explore 384 炎症组II、Explore 384 神经科学组、Explore 384 神经科学组II、Explore 384 肿瘤组、Explore 384 肿瘤组II。本数据集关联于题为《识别与长新冠不同临床表现相关的可溶性生物标志物》的研究论文，该论文原标题为"Identification of soluble biomarkers that associate with distinct manifestations of long COVID"。